Chronic graft-versus-host-disease treatment in Brazil: analyses of failure-free survival.

[1]  M. Flowers,et al.  Impact of mother donor, peripheral blood stem cells and measurable residual disease on outcomes after haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide in children with acute leukaemia , 2021, Bone Marrow Transplantation.

[2]  L. Bouzas,et al.  DIAGNOSIS AND TREATMENT OF GVHD , 2021, JBMTCT.

[3]  L. Bouzas,et al.  Hematopoietic cell transplantation in pediatric patients with acute leukemias or myelodysplastic syndrome using unrelated adult or umbilical cord blood donors in Brazil , 2020, Pediatric transplantation.

[4]  J. Garcia,et al.  Outcomes after Haploidentical Stem Cell Transplantation with Post-Transplantation Cyclophosphamide in Patients with Primary Immunodeficiency Diseases. , 2020, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  E. Holler,et al.  Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation-Results from a Single-Center Observational Study. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[6]  Stephanie J. Lee,et al.  Translation, Cross-Cultural Adaptation, and Validation of the Lee Chronic Graft-versus-Host Disease Symptom Scale in a Brazilian Population. , 2016, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[7]  P. Campregher,et al.  Survival and graft‐versus‐host disease in patients receiving peripheral stem cell compared to bone marrow transplantation from HLA‐matched related donor: retrospective analysis of 334 consecutive patients , 2015, European journal of haematology.

[8]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[9]  J. Pidala,et al.  Failure-free survival in a prospective cohort of patients with chronic graft-versus-host disease , 2015, Haematologica.

[10]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[11]  W. Wood,et al.  Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease. , 2014, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  B. Sandmaier,et al.  Failure-free survival after initial systemic treatment of chronic graft-versus-host disease. , 2014, Blood.

[13]  S. Svegliati,et al.  Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD. , 2013, Blood.

[14]  J. Shelhamer,et al.  National Institutes of Health chronic graft-versus-host disease staging in severely affected patients: organ and global scoring correlate with established indicators of disease severity and prognosis. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[15]  B. Sandmaier,et al.  Failure-free survival after second-line systemic treatment of chronic graft-versus-host disease. , 2013, Blood.

[16]  B. Kurland,et al.  Analysis of gastrointestinal and hepatic chronic graft-versus-host [corrected] disease manifestations on major outcomes: a chronic graft-versus-host [corrected] disease consortium study. , 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[17]  B. Storer,et al.  Poor agreement between clinician response ratings and calculated response measures in patients with chronic graft-versus-host disease. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  B. Storer,et al.  Clinical benefit of response in chronic graft-versus-host disease. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[19]  J. Miguel,et al.  Evaluation of prognostic factors among patients with chronic graft-versus-host disease , 2012, Haematologica.

[20]  J. Klein,et al.  Chronic GVHD risk score: a Center for International Blood and Marrow Transplant Research analysis. , 2011, Blood.

[21]  L. Bouzas,et al.  Brazilian workshop model to train investigators in chronic graft-versus-host disease clinical trials according to the 2005-2006 National Institutes of Health recommendations , 2011, Revista brasileira de hematologia e hemoterapia.

[22]  B. Storer,et al.  Comparison of short-term response and long-term outcomes after initial systemic treatment of chronic graft-versus-host disease. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[23]  L. Bouzas,et al.  A multicenter feasibility study of chronic graft-versus-host disease according to the National Institute of Health criteria: efforts to establish a Brazil-Seattle consortium as a platform for future collaboration in clinical trials , 2011, Revista brasileira de hematologia e hemoterapia.

[24]  B. Storer,et al.  Evaluation of NIH consensus criteria for classification of late acute and chronic GVHD. , 2009, Blood.

[25]  J. Fay,et al.  Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease. , 2009, Blood.

[26]  Steven Hirschfeld,et al.  Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report , 2006 .

[27]  R. Storb,et al.  Duration of immunosuppressive treatment for chronic graft-versus-host disease. , 2004, Blood.

[28]  M. Flowers,et al.  Chronic graft-versus-host disease. , 2003, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[29]  R. Storb,et al.  Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial. , 2002, Blood.

[30]  J. V. Stone,et al.  Long-Term Survival and Late Deaths after Allogeneic Bone Marrow Transplantation , 1999 .

[31]  J Crowley,et al.  Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. , 1999, Statistics in medicine.